UBS Group’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q3 | – | Sell |
-13,084
| Closed | -$236K | – | 8820 |
|
|
2020
Q2 | $236K | Sell |
13,084
-115,527
| -90% | -$1.61M | ﹤0.01% | 4685 |
|
|
2020
Q1 | $917K | Buy |
128,611
+101,924
| +382% | +$1.27M | ﹤0.01% | 3427 |
|
|
2019
Q4 | $638K | Sell |
26,687
-162,086
| -86% | -$4.47M | ﹤0.01% | 4620 |
|
|
2019
Q3 | $5.06M | Sell |
188,773
-3,942
| -2% | -$111K | ﹤0.01% | 2370 |
|
|
2019
Q2 | $5.23M | Buy |
192,715
+45,910
| +31% | +$1.44M | ﹤0.01% | 2296 |
|
|
2019
Q1 | $5.09M | Sell |
146,805
-188,479
| -56% | -$5.44M | ﹤0.01% | 2191 |
|
|
2018
Q4 | $6.54M | Buy |
335,284
+180,279
| +116% | +$3.71M | ﹤0.01% | 1923 |
|
|
2018
Q3 | $4.13M | Buy |
155,005
+81,342
| +110% | +$2.66M | ﹤0.01% | 2525 |
|
|
2018
Q2 | $2.78M | Sell |
73,663
-73,738
| -50% | -$2.82M | ﹤0.01% | 2856 |
|
|
2018
Q1 | $4.81M | Buy |
147,401
+99,764
| +209% | +$4.38M | ﹤0.01% | 2354 |
|
|
2017
Q4 | $2.32M | Sell |
47,637
-9,878
| -17% | -$500K | ﹤0.01% | 3065 |
|
|
2017
Q3 | $3.11M | Buy |
57,515
+46,768
| +435% | +$2.75M | ﹤0.01% | 2669 |
|
|
2017
Q2 | $603K | Buy |
10,747
+5,990
| +126% | +$240K | ﹤0.01% | 3987 |
|
|
2017
Q1 | $187K | Buy |
4,757
+2,266
| +91% | +$72.2K | ﹤0.01% | 4688 |
|
|
2016
Q4 | $56K | Sell |
2,491
-611
| -20% | -$11.9K | ﹤0.01% | 5738 |
|
|
2016
Q3 | $70K | Sell |
3,102
-30,182
| -91% | -$708K | ﹤0.01% | 5248 |
|
|
2016
Q2 | $786K | Buy |
33,284
+29,771
| +847% | +$735K | ﹤0.01% | 3577 |
|
|
2016
Q1 | $72K | Sell |
3,513
-21,470
| -86% | -$681K | ﹤0.01% | 5219 |
|
|
2015
Q4 | $1.29M | Sell |
24,983
-2,847
| -10% | -$138K | ﹤0.01% | 3197 |
|
|
2015
Q3 | $1.19M | Buy |
27,830
+25,596
| +1,146% | +$1.24M | ﹤0.01% | 3203 |
|
|
2015
Q2 | $101K | Sell |
2,234
-1,441
| -39% | -$58K | ﹤0.01% | 5399 |
|
|
2015
Q1 | $139K | Buy |
3,675
+500
| +16% | +$17.2K | ﹤0.01% | 5171 |
|
|
2014
Q4 | $90K | Buy |
+3,175
| New | +$88.3K | ﹤0.01% | 5809 |
|
UBS Group's PTLA Position: Q3 2020 in Review
UBS Group sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q3 2020, closing a stake of 13,084 shares — an estimated $236K sold.
UBS Group first reported a position in PTLA in Q4 2014 and held it in 23 quarters. The position peaked at $6.54M in Q4 2018. 0 funds tracked by Wall St. Rank hold PTLA as of Q3 2020.
- UBS Group reported no remaining Portola Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
- UBS Group sold 13,084 Portola Pharmaceuticals, Inc. shares in Q3 2020, an estimated $236K.
- UBS Group first reported a position in Portola Pharmaceuticals, Inc. in Q4 2014 and held it in 23 quarters.
- UBS Group's Portola Pharmaceuticals, Inc. position peaked at $6.54M in Q4 2018.
- 0 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q3 2020.
Based on UBS Group's 13F filing for Q3 2020, filed 12 Nov 2020.